Skip to content
NovAccess Global Logo
XSNX 0.00 0.00 0.00%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
NovAccess Global Logo
XSNX 0.00 0.00 0.00%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact

Category: NovAccess Global Press Releases

NovAccess Global Announces Fireside Chat Series for the Investment Community

XSNX Fireside Chat

NovAccess Global Announces Effectiveness of Form S1 Registration Statement

NovAccess Global Announces Uplisting to OTCQB

NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1

Orphan Drug Application Filing

 NovAccess Global CEO Dwain Irvin Featured on MoneyTV 

NovAccess Global to Participate in LD Micro Invitational XII Conference

NovAccess Global Closes its Redemption Transaction and expands the Executive Board

NovAccess Global, Inc.’s CEO to attend BIO Conference in New York

NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer

Neil Laird

NovAccess Global, Inc. Expands Advisory Board

NovAccess Global Announces $10.7 Million Financing
← older
newer →

Revolutionary advances in the  understanding of how our bodies can fight cancer, and how to put that information to use in treating existing tumors. NovAccess Global’s team of experts is working to strengthen the capability of the human body’s defense against cancer.

Youtube Facebook Twitter Linkedin

Privacy Policy

Forward-Looking Statements

Contact Us

  • info@novaccessglobal.com
  • Corporate HQ
  • 459 Columbus Ave. #607
    New York, NY 10025
  • Research & Development
  • 2265 E. Foothill Blvd, Pasadena, CA 91107

JOIN US

Stay up-to-date with our journey

Facebook Twitter Linkedin

Privacy Policy

Privacy Policy

Forward-Looking Statements